

## CLAIMS

1. Topical treatment of psoriasis with formulations (creams, gels,...) to accomplish non-physiologic high concentrations of Epidermal Growth Factor (EGF), which can down-regulate the expression of the EGF-Receptor .
2. Psoriasis treatment with topical formulations ,containing EGF in concentrations of 0.01 to 50 micrograms/ gram.
3. Topical formulations containing 0.5-20 microgram EGF / gram of formulation .
4. Topical creams , containing 0.1-3% sulfadiazine and 0.5-20 micrograms EGF / gram for the treatment of psoriasis.
5. Topical formulations, containing anti-inflammatory products , in combination with epidermal growth factor.
6. Topical formulations, containing EGF in combination with anti-inflammatory products and other dermatologically-beneficial products , for the treatment of psoriasis.
7. Topical formulations , containing 10 µg EGF and 1% of sulfadiazine for the treatment of psoriasis.
8. Systemic treatment of psoriasis patients with 0.001 – 10 microgram of EGF / kg.
9. Topical and systemic treatment of psoriasis patients with precursor molecules of epidermal growth factor ,such as fibroblast growth factor.
10. Treatment with products, with similar biological action as EGF, such as urogastrone or fractions of the EGF molecule.

002201.249582